Your browser doesn't support javascript.
loading
Licarin A as a Novel Drug for Inflammatory Eye Diseases.
Paiva, Mayara Rodrigues Brandão de; Vasconcelos-Santos, Daniel Vítor de; Coelho, Márcio Matos; Machado, Renes Resende; Lopes, Norberto Peporine; Silva-Cunha, Armando; Fialho, Silvia Ligório.
Afiliação
  • Paiva MRB; Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Vasconcelos-Santos DV; Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Coelho MM; Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Machado RR; Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Lopes NP; NPPNS, Department of Biomolecular Sciences, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
  • Silva-Cunha A; Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Fialho SL; Pharmaceutical Research and Development, Ezequiel Dias Foundation, Belo Horizonte, Brazil.
J Ocul Pharmacol Ther ; 37(5): 290-300, 2021 06.
Article em En | MEDLINE | ID: mdl-33761287
Purpose: This study investigated the safety and therapeutic efficacy of licarin A (LCA) in the treatment of intraocular inflammation. Methods:In vitro safety of LCA in retinal pigmented epithelial cells (ARPE-19) and human embryonic stem cell derived-retinal pigmented epithelial cells (hES-RPE) was evaluated using CellTiter-Blue® kit. The chorioallantoic membrane (CAM) assay was used to investigate LCA safety and antiangiogenic activity. In vivo safety of intravitreal LCA was accomplished by clinical examination (including assessment of intraocular pressure), electroretinography (ERG), and histopathology. Uveitis was induced in rats by subcutaneous and intravitreal injection of bacillus Calmette-Guérin (BCG) antigen of Mycobacterium bovis. Intraocular inflammation was graded by slit-lamp and fundus examination, ERG, and histopathology. Results: LCA was safe to cells and to the CAM at concentration below 12.0 µM. LCA significantly reduced the percentage of blood vessels in the CAM. Retinal safety and anti-inflammatory efficacy of intravitreal injection of LCA 6.0 µM were confirmed through clinical, functional, and histopathological evaluation. Significant reduction of inflammatory cytokines (tumor necrosis factor-α and interleukin-6) was also found, when compared to untreated animals. Conclusion: The results suggest that LCA is a potential new drug for the treatment of inflammatory eye disease.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Lignanas / Inibidores da Angiogênese / Epitélio Pigmentado da Retina / Inflamação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals Idioma: En Revista: J Ocul Pharmacol Ther Assunto da revista: FARMACOLOGIA / OFTALMOLOGIA / TERAPEUTICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Lignanas / Inibidores da Angiogênese / Epitélio Pigmentado da Retina / Inflamação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals Idioma: En Revista: J Ocul Pharmacol Ther Assunto da revista: FARMACOLOGIA / OFTALMOLOGIA / TERAPEUTICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Estados Unidos